Government Imposes Strict Shelf-Life Mandates for Imported Pharmaceuticals

The central government has enforced stricter regulations governing the import of foreign medicines by introducing mandatory minimum shelf-life requirements upon entry. Under the updated framework, standard imported pharmaceutical products must possess at least seventy percent of their labelled shelf-life remaining when they arrive in the country. For specialized categories, specifically biological drugs and radiopharmaceuticals, a separate threshold has been provided that permits imports where sixty percent of the labelled shelf-life is met. This regulatory update addresses previous gaps in import quality control by ensuring that incoming medical inventories retain sufficient viability before reaching domestic consumers and patients.

Previously, import rules lacked these specific percentage-based thresholds across various drug classifications, leading to inconsistencies in product freshness. The new mandate brings clarity for pharmaceutical importers and customs authorities by establishing clear, distinct criteria for standard medicines versus biological and radiopharmaceutical products. Importers, logistics handlers, and compliance professionals must review their supply chain timelines and supplier agreements to guarantee that all incoming shipments meet the seventy percent or sixty percent thresholds prior to dispatch.

Tax and trade advisors should inform pharmaceutical clients about these strict verification standards to prevent port detentions and costly shipment rejections. Stakeholders need to track official customs notifications for any further operational guidelines regarding documentation requirements for these shelf-life verifications.